EP 0551294 A4 19931229 - RIBOZYME INHIBITION OF BCR-ABL GENE EXPRESSION
Title (en)
RIBOZYME INHIBITION OF BCR-ABL GENE EXPRESSION
Publication
Application
Priority
- CA 2092571 A 19910801
- US 9105443 W 19910801
Abstract (en)
[origin: CA2092571A1] 2092571 9303141 PCTABS00019 Ribozymes effective to inhibit bcr-abl expression and the use of ribozymes to block proliferation of leukemia carrying the bcr-abl gene are disclosed. E. Coli transfected with the requisite ribozyme gene provides significant quantities thereof.
IPC 1-7
IPC 8 full level
A61K 48/00 (2006.01); A61P 35/02 (2006.01); C07K 14/82 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 9/00 (2006.01); C12N 15/09 (2006.01); C12N 15/113 (2010.01); C12R 1/19 (2006.01); C12R 1/91 (2006.01)
CPC (source: EP)
A61P 35/02 (2017.12); C07K 14/82 (2013.01); C12N 15/1135 (2013.01); C12N 2310/111 (2013.01); C12N 2310/121 (2013.01)
Citation (search report)
- [A] WO 9104753 A1 19910418 - CETUS CORP [US]
- [E] WO 9200080 A1 19920109 - WISTAR INST [US]
- [A] TRENDS IN BIOTECHNOLOGY vol. 8, no. 7, July 1990, CAMBRIDGE GB pages 174 - 178 COTTEN, M. 'The in vivo application of ribozymes'
- [A] SCIENCE vol. 245, 8 September 1989, LANCASTER, PA US pages 1107 - 1110 CARACCIOLO, D. ET AL. 'Lineage-specific requirement of c-abl function in normal hematopoiesis'
- See references of WO 9303141A1
Designated contracting state (EPC)
DE FR GB
DOCDB simple family (publication)
CA 2092571 A1 19930202; EP 0551294 A1 19930721; EP 0551294 A4 19931229; JP H06501610 A 19940224
DOCDB simple family (application)
CA 2092571 A 19910801; EP 91915940 A 19910801; JP 51464991 A 19910801